Maravai LifeSciences (MRVI) Q4 2024 earnings summary

Executive summary

• 2024 was a challenging year with revenue of $259M, a GAAP net loss of $260M, and adjusted EBITDA of $36M, impacted by lower CleanCap® sales and a non-cash goodwill impairment charge of $11.9M.

• Q4 2024 revenue was $57M, net loss was $46M, and adjusted EBITDA was negative $1M.

• The company completed two acquisitions in early 2025, enhancing discovery and design capabilities, and expanded distribution in EMEA.

• Focus remains on innovation, expanding the customer base, protecting IP, and managing costs for long-term growth.

• Voluntarily prepaid $228M in debt, ending 2024 with $322M in cash and $22M net cash position.

Financial highlights

• FY 2024 revenue was $259M; Q4 revenue was $57M.

• GAAP net loss for FY 2024 was $260M; Q4 net loss was $46M.

• Adjusted EBITDA for FY 2024 was $36M (14% margin); Q4 adjusted EBITDA was negative $1M.

• Ended 2024 with $322M in cash, $300M in long-term debt, and $22M net cash.

• Voluntarily paid down $228M in debt in December 2024.

Outlook and guidance

• 2025 base business revenue guidance is $185–$205M, with low single-digit growth at the midpoint.

• No binding commitments for high-volume CleanCap® in 2025; guidance excludes COVID vaccine-related revenue.

• Q1 2025 revenue expected at $43–$45M, slightly above Q4 2024 base business.

• Not expecting positive adjusted EBITDA at current revenue levels; no profitability guidance for 2025.

• CapEx expected to decline to $15–$20M in 2025, with further reductions in 2026.